scholarly journals The platelet-rich plasma lysate use in the treatment of persistent epithelial defects after keratoplasty

2021 ◽  
Vol 14 (2) ◽  
pp. 27-35
Author(s):  
Nare P. Shakhbazyan ◽  
Sergey V. Trufanov ◽  
Anastasia M. Subbot
Keyword(s):  
Adjuvant Therapy ◽  
Effective Treatment ◽  
Standard Therapy ◽  
Platelet Rich Plasma ◽  
Corneal Transplantation ◽  
Low Risk ◽  
Postoperative Therapy ◽  
Persistent Epithelial Defects

AIM:to evaluate the effectiveness of the platelet-rich plasma lysate (PRP lysate) use in the treatment of persistent epithelial defects (PED) after keratoplasty. MATERIALS AND METHODS:In the study, 60 patients with PED after keratoplasty were included. The 1st group (24 cases)included patients after keratoplasty with low risk of rejection, and the 2nd group 36 cases after keratoplasty with highrisk of rejection. Each group was divided into two subgroupscontrol subgroups 1a (cases 10) and 2a (cases 16), where patients received only standard postoperative therapy, and the main subgroups 1b (cases 14) and 2b (cases 20), in which PRP lysate was prescribed against the background of standard therapy, starting from the Day 15 post-op. As the criterion for effective treatment, complete persistent epithelialization after keratoplasty was considered. RESULTS:The effectiveness of the use of PRP lysate in the subgroup 1b was 85.7%, while complete epithelialization in the control subgroup 1a was recorded in 70%; in the subgroup 2b, complete epithelialization was observed in 55%, in the control subgroup 2ain 43.75%. CONCLUSION:The use of PRP lysate in the treatment of PED after corneal transplantation as an adjuvant therapy is effective and safe in both high and low risk keratoplasty. In the examined category of patients, treatment with blood derivatives increases the frequency and rate of complete epithelialization.

Preenchimento facial com uso de material autólogo plasma gel - relato de caso

2021 ◽  
Vol 2 (6) ◽  
pp. 28-35
Author(s):  
Viviane Rozeira Crivellaro ◽  
Ane Micheline M. Oliveira ◽  
Julyana Gois ◽  
Paula Ferreira Martelozzo
Keyword(s):  
Case Report ◽  
Platelet Rich Plasma ◽  
Low Risk ◽  
Filling Material ◽  
Safe Option ◽  
Subsequent Heating

This case report demonstrates the use of plasma gelas a chin filler. Plasma gel is a material obtained from platelet-rich plasma (PRP) and its subsequent heating in an incubator.It is a safe option in relation to other fillers because it is an autologous biomaterial and therefore with low risk of immunoreaction. The chin was filled in bollus in the central part and with the tunneling technique on the sides. 0.2 mL of plasma gelwere used at each point, totaling 0.6 mL of the biomaterial. The protocol for this case was one session, with a reassessment after 28 days. Plasma gel proved to be effective as a temporary facial filling material. However, studies on its durability are lacking.

scholarly journals Contrast-Enhanced Ultrasound Evaluation of Mifepristone for Treatment of Low-Risk Cesarean Scar Pregnancy

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Xi Xiong ◽  
Chun-yan Gao ◽  
De-mei Ying ◽  
Ping Yan ◽  
Zhi-jia Zhang ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Low Risk ◽  
Contrast Enhanced Ultrasound ◽  
Intrauterine Pregnancy ◽  
Cesarean Scar Pregnancy ◽  
Cesarean Scar ◽  
Ultrasound Evaluation ◽  
Contrast Enhanced ◽  
Significant Difference ◽  
Before And After

Purpose. The effect of mifepristone for treatment of low-risk cesarean scar pregnancy (CSP) was monitored by contrast-enhanced ultrasound (CEUS). Methods. Data were collected from 23 CSP patients with a 10-point risk score <5 (low-risk CSP) and from 23 intrauterine pregnancy (IUP) patients with a scar from a previous cesarean delivery. All patients were prescribed 75 mg mifepristone daily for 2 days and underwent transvaginal CEUS before and after administration of mifepristone. On the third day, uterine curettage was performed after transvaginal CEUS. Arrival time (AT), peak intensity (PI), and area under the curve (AUC) around the gestational sac were monitored by CEUS before and after application of mifepristone, and the rate of effective treatment was compared between the two patient groups. Results. No patients experienced side effects from either the CEUS procedure or the mifepristone treatment. Changes in AT, PI, and AUC index from before vs. after mifepristone treatment did not differ significantly between the two groups (all p values >0.05). There was also no significant difference in the rate of effective treatment between the two groups (95.65% in the CSP group vs. 100% in the IUP group; p > 0.05 ). Conclusions. Based on monitoring by CEUS, the effect of mifepristone in low-risk CSP was comparable to that in IUP.

Intra-articular Injection of Pure Platelet-Rich Plasma Is the Most Effective Treatment for Joint Pain by Modulating Synovial Inflammation and Calcitonin Gene-Related Peptide Expression in a Rat Arthritis Model

2020 ◽  
Vol 48 (8) ◽  
pp. 2004-2012 ◽  
Author(s):  
Naoko Araya ◽  
Kazumasa Miyatake ◽  
Kunikazu Tsuji ◽  
Hiroki Katagiri ◽  
Yusuke Nakagawa ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Synovial Tissue ◽  
Joint Pain ◽  
Platelet Rich Plasma ◽  
Calcitonin Gene Related Peptide ◽  
Nerve Fibers ◽  
Synovial Inflammation ◽  
Arthritis Model ◽  
Related Peptide ◽  
Calcitonin Gene

Background: Platelet-rich plasma (PRP) has emerged as a treatment for osteoarthritis (OA). However, the effect that leukocyte concentrations in PRP have on OA remains unclear. Purpose: To clarify the optimal PRP formulation for OA treatment by comparing pure PRP, leukocyte-poor PRP (LP-PRP), and leukocyte-rich PRP (LR-PRP) in a rat arthritis model. Study Design: Controlled laboratory study. Methods: Knee arthritis was induced bilaterally in male Wistar rats with intra-articular injections of monosodium iodoacetate (MIA) on day 0. Rats were randomly assigned to 1 of 3 treatment groups (pure PRP, LP-PRP, and LR-PRP). On day 1, allogenic PRP was injected into the right knee of rats and phosphate-buffered saline was injected into the left knee as a control. Weight distribution on the hindlimbs was measured for 14 days to assess pain behavior. Rats were euthanized at day 5 or 14 for histological assessment of synovial tissue and cartilage. Immunohistochemical staining of calcitonin gene-related peptide (CGRP) and α-smooth muscle actin was performed to determine the mechanism of pain relief induced by the PRP preparations. Results: In all groups, PRP increased the load-sharing ratio on PRP-injected knees, with pure PRP eliciting the largest effect among the 3 kinds of PRP ( P < .05). Structural changes in the synovial tissue were significantly inhibited in the pure-PRP group compared with the control group after both 5 and 14 days ( P < .001 and P = .025, respectively), whereas no significant difference was found between the control, LP-PRP, and LR-PRP groups. An inhibitory effect on cartilage degeneration was observed only in the pure-PRP group on day 14. Pure PRP also significantly inhibited expression of CGRP-positive nerve fibers in the infrapatellar fat pad compared with the other groups ( P < .05). Conclusion: In an MIA-induced arthritis model, pure PRP injection was the most effective treatment for reduction of pain-related behavior and inhibition of synovial inflammation and pain sensitization. Clinical Relevance: PRP formulations should be optimized for each specific disease. This study shows the superiority of pure PRP for treatment of arthritis and joint pain.

Platelet-rich plasma-induced feedback inhibition of activin A/follistatin signaling: A mechanism for tumor-low risk skin rejuvenation in irradiated rats

2018 ◽  
Vol 180 ◽  
pp. 17-24 ◽  
Author(s):  
Nesreen Nabil Omar ◽  
Rasha R. Rashed ◽  
Rania M. El-Hazek ◽  
Walaa A. El-Sabbagh ◽  
Engy R. Rashed ◽  
...  
Keyword(s):  
Feedback Inhibition ◽  
Platelet Rich Plasma ◽  
Activin A ◽  
Low Risk ◽  
Skin Rejuvenation

scholarly journals Recurrence and progression of non-muscle invasive bladder cancer following trans-urethral resection of bladder tumour with adjuvant intravesical chemo-immunotherapy

2020 ◽  
Vol 10 (3) ◽  
pp. 34-38
Author(s):  
Ashok Kumar Kunwar ◽  
Kabir Tiwari ◽  
Sanjesh Bhakta Shrestha ◽  
Srijana Thapa ◽  
Ashish Kumar Panthee ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Effective Treatment ◽  
Risk Group ◽  
Bladder Tumour ◽  
Low Risk ◽  
Invasive Bladder Cancer ◽  
Intermediate Risk ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Background: Trans-urethral resection of bladder tumor is an essential diagnostic tool as well as effective treatment modality for non-muscle invasive bladder cancer. We aimed to evaluate the recurrence and progression of the non-muscle invasive bladder cancer in Nepalese patients. Methods: This was a retrospective study of 43 patients with non-muscle invasive bladder cancer, who underwent trans-urethral resection of bladder tumour followed by adjuvant intravesical instilla­tion of chemo or immunotherapy between January, 2013 to December, 2018. Patients were divided into low, intermediate and high-risk groups according to the clinical and pathological factors used by the European Organization for Research and Treatment of Cancer scoring system. Outcomes were calculated in terms of recurrence and progression in each group. Results: Out of 43 patients, 11 (25.58%) patients had low risk, 18 (41.86%) patients had intermediate risk and 14 (32.56%) patients had high risk of recurrence categories. No recurrence and progression of the disease noted in low risk group. In the intermediate risk group, out of 18 patients, 4 (22.2%) patients developed recurrence and 2 (11.1%) patients had progression of disease. In high risk group, out of 14 patients, 4 (26.8%) patients developed recurrence and 2 (14%) patients developed progres­sion of the disease. Conclusions: Even in a low volume centre of bladder cancer, effective treatment for non-muscle inva­sive bladder cancer with trans-urethral resection of bladder tumour followed by adjuvant intravesical chemo or immunotherapy can be given safely to reduce recurrence and progression of the disease.

Is MUGA Scan Necessary in Patients With Low-Risk Breast Cancer Before Doxorubicin-Based Adjuvant Therapy?

2001 ◽  
Vol 24 (4) ◽  
pp. 425-428 ◽  
Author(s):  
Michael S. Sabel ◽  
Ellis G. Levine ◽  
Thelma Hurd ◽  
Gary N. Schwartz ◽  
Robert Zielinski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Low Risk ◽  
Risk Breast Cancer

Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3510-3510 ◽  
Author(s):  
Ramon Salazar ◽  
Josep Tabernero ◽  
Victor Moreno ◽  
Ulrich Nitsche ◽  
Thomas Bachleitner-Hofmann ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Lower Risk ◽  
Low Risk ◽  
Stage Ii ◽  
Disease Relapse ◽  
Risk Of Disease

3510 Background: Adjuvant therapy for stage II patients is recommended for patients with high risk features, especially with T4 tumors. Adjuvant therapy is not indicated for patients with MSI-H status who are considered of being at low risk of disease relapse. However, this leaves the majority of patients with an undetermined risk. ColoPrint is an 18-gene expression classifier that identifies early-stage colon cancer patients at higher risk of disease relapse. Methods: ColoPrint was developed using whole genome expression data and was validated in public datasets (n=322) and independent patient cohorts from 5 European hospitals. Tissue specimen, clinical parameters, MSI-status and follow-up data (median follow-up 70 months) for patients were available and the ColoPrint index was determined using validated diagnostic arrays. Uni-and multivariate analysis was performed on the pooled stage II patient set (n=320) and the subset of patients who were T3/ MSS (n=227). Results: In the analysis of all stage II patients, ColoPrint classified two-third of stage II patients as being at lower risk. The 3-year Relapse-Free-Survial (RFS) RFS was 91% for Low Risk and 74% for patients at higher risk with a HR of 2.9 (p=0.001). Clinicopathological parameters from the ASCO recommendations (T4, perforation, <12 LN assessed, and/ or high grade) or NCCN guidelines (ASCO factors plus angio-lymphatic invasion) did not predict a differential outcome for high risk patients (p< 0.20). In the subgroup of patients with T3 and MSS phenotype, ColoPrint classified 61% of patients at lower risk with a 3-year RFS of 91% (86-96%) and 39% of patients at higher risk with a 3-year RFS of 73% (63-83%) (p=0.002). No clinical parameter was significantly prognostic in this subgroup. Conclusions: ColoPrint combined with established clinicopathological factors and MSI, significantly improves prognostic accuracy, thereby facilitating the identification of patients at higher risk who might be considered for additional treatment.

scholarly journals Platelet-rich plasma by single spin process in male pattern androgenetic alopecia: Is it an effective treatment?

2017 ◽  
Vol 8 (6) ◽  
pp. 460 ◽  
Author(s):  
Azin Ayatollahi ◽  
Hamed Hosseini ◽  
Majid Shahdi ◽  
Saman AhmadNasrollahi ◽  
Mansour NassiriKashani ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Single Spin ◽  
Male Pattern
Sign in / Sign up

Export Citation Format

Share Document